CA2536807C - Vecteur d'expression - Google Patents

Vecteur d'expression Download PDF

Info

Publication number
CA2536807C
CA2536807C CA2536807A CA2536807A CA2536807C CA 2536807 C CA2536807 C CA 2536807C CA 2536807 A CA2536807 A CA 2536807A CA 2536807 A CA2536807 A CA 2536807A CA 2536807 C CA2536807 C CA 2536807C
Authority
CA
Canada
Prior art keywords
gene
expression vector
promoter
expression
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2536807A
Other languages
English (en)
Other versions
CA2536807A1 (fr
Inventor
Amelia Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of CA2536807A1 publication Critical patent/CA2536807A1/fr
Application granted granted Critical
Publication of CA2536807C publication Critical patent/CA2536807C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention a trait à des acides nucléiques et à des vecteurs d'expression, et des cellules hôtes transformées par ceux-ci, pour assurer une expression élevée d'un polypeptide souhaité. L'invention a également trait à des procédés mettant en oeuvre les vecteurs d'expression, des acides nucléiques, et des cellules hôtes qui ont été modifiées par ces compositions, pour l'accroissement de l'expression d'un gène codant pour un polypeptide souhaité.
CA2536807A 2003-09-04 2004-09-03 Vecteur d'expression Expired - Lifetime CA2536807C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50080303P 2003-09-04 2003-09-04
US60/500,803 2003-09-04
PCT/US2004/028954 WO2005024015A1 (fr) 2003-09-04 2004-09-03 Vecteur d'expression

Publications (2)

Publication Number Publication Date
CA2536807A1 CA2536807A1 (fr) 2005-03-17
CA2536807C true CA2536807C (fr) 2010-07-13

Family

ID=34272998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2536807A Expired - Lifetime CA2536807C (fr) 2003-09-04 2004-09-03 Vecteur d'expression

Country Status (7)

Country Link
US (1) US7674618B2 (fr)
EP (1) EP1660654B1 (fr)
JP (1) JP4751326B2 (fr)
AT (1) ATE532861T1 (fr)
CA (1) CA2536807C (fr)
ES (1) ES2374526T3 (fr)
WO (1) WO2005024015A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
ES2625798T3 (es) 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
EP2097097B1 (fr) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Anticorps, en particulier anticorps humains, se liant a cd22 et utilisations de ceux-ci
AU2007352618B2 (en) * 2007-05-02 2013-07-18 Boehringer Ingelheim Animal Health USA Inc. DNA plasmids having improved expression and stability
RU2456346C2 (ru) * 2007-05-02 2012-07-20 Мериал Лимитед Днк-плазмиды, обладающие повышенной экспрессией и стабильностью
JP5960947B2 (ja) * 2007-12-19 2016-08-02 グライコフィ， インコーポレイテッド タンパク質の製造のための酵母株
PT2227546T (pt) 2007-12-21 2016-08-12 Novartis Ag Vector de expressão em mamíferos
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP4491808B1 (ja) * 2009-06-05 2010-06-30 東洋紡績株式会社 高発現細胞の効率的な選別に有用な薬剤選択マーカー遺伝子発現カセット
JP4525863B1 (ja) * 2009-06-05 2010-08-18 東洋紡績株式会社 高生産性細胞の樹立のための発現ベクター及び高生産性細胞
JP4547643B1 (ja) * 2009-06-05 2010-09-22 東洋紡績株式会社 クローニングに最適化された発現ベクター
SI2776032T1 (sl) 2011-11-09 2018-12-31 Bristol-Myers Squibb Company Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom
BR112018073316A2 (pt) 2016-05-11 2019-06-04 Amgen Inc seleção direta de células que expressam altos níveis de proteínas heteroméricas usando vetores de complementação intragênica da glutamina sintetase
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
WO2020117910A1 (fr) * 2018-12-04 2020-06-11 Catalent Pharma Solutions, Llc Vecteurs pour la fabrication de protéines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
DE68929419T2 (de) 1988-12-13 2003-04-03 Colorado State University Research Foundation, Fort Collins Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff
US5256568A (en) * 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
WO1992001800A1 (fr) 1990-07-20 1992-02-06 Chiron Corporation Procede de transformation integrante de levure au moyen d'elements repetitifs disperses
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
ES2088838T3 (es) 1992-11-13 2004-01-01 Idec Pharmaceuticals Corporation Secuencias kozak de consenso totalmente alteradas destinadas a la expresion en los mamiferos.
US5627033A (en) * 1995-03-28 1997-05-06 Research & Diagnostics Systems, Inc. Mammalian expression vectors
US5928941A (en) * 1996-10-07 1999-07-27 President And Fellows Of Harvard College Repressor kruppel-like factor
BR9808584A (pt) * 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US6444421B1 (en) * 1997-11-19 2002-09-03 The United States Of America As Represented By The Department Of Health And Human Services Methods for detecting intermolecular interactions in vivo and in vitro
AU2400500A (en) 1999-11-01 2001-05-14 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
US20040029229A1 (en) * 2002-05-20 2004-02-12 Reeves Philip J. High level protein expression system

Also Published As

Publication number Publication date
US20050153394A1 (en) 2005-07-14
CA2536807A1 (fr) 2005-03-17
ATE532861T1 (de) 2011-11-15
JP2007503837A (ja) 2007-03-01
EP1660654B1 (fr) 2011-11-09
EP1660654A4 (fr) 2007-08-22
ES2374526T3 (es) 2012-02-17
JP4751326B2 (ja) 2011-08-17
US7674618B2 (en) 2010-03-09
WO2005024015A1 (fr) 2005-03-17
EP1660654A1 (fr) 2006-05-31

Similar Documents

Publication Publication Date Title
US7674618B2 (en) Expression vector
US7235360B2 (en) Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US5830698A (en) Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
USRE49347E1 (en) Mammalian expression vector
CN102165060A (zh) 新的调控组件
EP1228237A1 (fr) Vecteurs d'expression, systemes de transfection et leur procede d'utilisation
EP1115852B1 (fr) Vecteurs d'expression contenant un point chaud permettant d'augmenter l'expression de proteines recombinantes dans des cellules transfectees
AU2004295590B2 (en) Expression systems using mammalian beta-actin promoter
US20200087679A1 (en) Expression cassette
ES2699718T3 (es) Células para expresión transitoria y usos de las mismas
KR101163295B1 (ko) 향상된 면역글로불린을 생산하는 중쇄 돌연변이체
WO2025049905A1 (fr) Co-expression de dnase dans des cellules hôtes
TR2025005329T2 (tr) Rekombi̇nant protei̇ni̇n yüksek veri̇m ve stabi̇l üreti̇mi̇ i̇çi̇n yeni̇ bi̇r ekspresyon platformu
HK1086298A (en) Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
HK1086299A (en) Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Legal Events

Date Code Title Description
EEER Examination request